Healthy individuals are generally immunologically tolerant to proteins derived from one’s self (termed self proteins). However, patients with monogenic clotting disorders, like hemophilia A (HemA), lack central tolerance to the absent self protein. Thus, when exposed to replacement therapy, such as procoagulant factor VIII, they may mount an immune response against the very self protein that is missing. In the current issue of the JCI, Becker-Gotot, Meissner, et al. present data on a possible mechanism for tolerance to factor VIII in healthy individuals and the immune response in patients, involving a role of PD-1 and T regulatory cells. The findings suggest that treatment with PD-1− and PD-1L− specific reagents may induce tolerance in patients with autoimmune disease, especially those with HemA who also possess inhibiting antibodies.
Until programmed death do us tolerant

David W. Scott

Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA.

Healthy individuals are generally immunologically tolerant to proteins derived from one’s self (termed self proteins). However, patients with monogenic clotting disorders, like hemophilia A (HemA), lack central tolerance to the absent self protein. Thus, when exposed to replacement therapy, such as procoagulant factor VIII, they may mount an immune response against the very self protein that is missing. In the current issue of the JCI, Becker-Gotot, Meissner, et al. present data on a possible mechanism for tolerance to factor VIII in healthy individuals and the immune response in patients, involving a role of PD-1 and T regulatory cells. The findings suggest that treatment with PD-1- and PD-L1-specific reagents may induce tolerance in patients with autoimmune disease, especially those with HemA who also possess inhibiting antibodies.

Hemophilia inhibitors

Patients with mutations in the F8 gene, encoding coagulation protein factor VIII (FVIII), have an X-linked bleeding disorder known as hemophilia A (HemA) and lack FVIII or functional FVIII protein (1, 2). These patients may suffer recurrent spontaneous bleeds or more serious trauma-induced bleeding crises and often experience substantial morbidity due to recurrent bleeding into the joints (3, 4). Standard treatment for HemA involves infusion of recombinant FVIII or plasma-derived FVIII on demand or prophylactically. However, up to 30% of treated patients develop antibodies that can block and inhibit the function of this life-saving therapy (4, 5) since they are not immunologically tolerant to this human protein. The antibodies that neutralize FVIII function, referred to as “inhibitors” (6), pose a major clinical challenge, as once formed, inhibitor titers are difficult to reduce or eliminate.

In this issue of the JCI, Becker-Gotot, Meissner, and colleagues (7) examined inhibitor formation in a mouse model for HemA (HemA mice). HemA mice, which have FVIII deficiency via removal of coding exon 16, were developed by Bi et al. (8) and have been used by researchers in the field for decades. Notably, nearly 100% of these HemA mice develop inhibitors to intravenously administered FVIII, whereas approximately 30% of patients with severe HemA develop clinically relevant inhibitors. We know that the immune response to FVIII is highly T (helper) cell dependent (9), but it is regulated in FVIII-sufficient mice (and humans) by T regulatory cells (Tregs) (10).

In previous studies, Gotot and colleagues provided evidence that the regulated immune response likely requires programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) interactions (11, 12), which leads to Treg-dependent apoptosis in wild-type (WT) mice. In contrast, HemA mice lack B cell tolerance to FVIII due to defective deletion, suppression, or receptor editing from lack of exposure to FVIII epitopes during development.

Seminal studies on tolerance mechanisms took advantage of B cell receptor-transgenic (BCR-transgenic) mice (13, 14) to follow the fate of antigen-specific B cells. However, these models are not yet available for FVIII-specific BCRs. Becker-Gotot, Meissner, et al. detected FVIII-specific B cells using Alexa Fluor 647-coupled FVIII, and then examined the Alexa Fluor 647-positive cells to analyze apoptosis directly in tolerized antigen-specific B cells: a tour de force, as such cells are rare in nontransgenic mice, occurring with a frequency of approximately 1/1000–1/2000. The flow cytometry approach was also challenging because FVIII is a relatively sticky protein with the ability to bind to other (e.g., endothelial) cell surfaces, so the specificity of FVIII binding to specific B cells is critical and this analysis needs to be validated, e.g., by competition with unlabeled FVIII or blocking with anti-IgM. Nonetheless, the authors found that the number of FVIII-specific B cells in naive mice (WT or HemA) was far lower than in immunized mice. A well-established principle is that tolerance to FVIII or other self-antigens in healthy mice is not broken in the absence of added adjuvants. In contrast, KO mice are expected to respond as we would to most antigens that we lack. Importantly, FVIII is very immunogenic even when given intravenously, a usually tolerogenic route. Whether this immunogenicity has to do with thrombin generation has been debated (15, 16).

Role of the PD-1/PD-L1 pathway in immune regulation

PD-L1 was first described by Honjo’s group in 1992 (17) and extensively studied by the Sharpe and Freeman groups at Harvard (11). PD-1 (also known as CD279) is an activation-induced member of the CD28/CTLA-4 family, known for suppressing conventional T cell responses (18), and allowing tumors to escape surveillance (19). Thus, PD-1 (or similar) blocking anti-

Related Article: https://doi.org/10.1172/JCI159925

Conflict of Interest: DWS holds patents titled “Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance” (US patent 5,817,308; European patent EP0741788-B1); “Cells expressing fusion proteins of immunoglobulins” (US patent 6,838,281; and “Design and use of specific regulatory T cells for tolerance” (US patent 10,093,901; EU patent 3001836).

Copyright: © 2022, Scott et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2022;132(22):e164858. https://doi.org/10.1172/JCI164858.
bodies have emerged with potential as anticancer drugs. Interestingly, patients treated with such PD-1 blocking antibodies often develop autoantibodies, a result suggesting that PD-1 has a critical role in immune regulation and tolerance (12).

PD-1 expression on FVIII-specific B cells in immunized HemA mice was lower than on those remaining antigen-specific B cells in WT animals, whereas annexin V-positive (indicating apoptotic) B cells were more evident in WT mice. This result suggested to the authors that PD-L1–bearing Tregs that recognize specific B cells that present FVIII peptides via MHC II were responsible for potentially deleting FVIII-specific B cells during developmental exposure to this self-antigen. Indeed, when Becker-Gotot, Meissner, et al. treated WT mice with an antibody that blocks PD-1 signaling, FVIII-specific B cells were rescued from deletion, allowing the cells to expand and produce anti-FVIII antibody. Moreover, a PD-1–stimulating antibody treatment in HemA mice led to suppression of anti-FVIII responsiveness. While the authors concede that other checkpoint inhibitors may be involved, their data support an import role of the PD-1/PD-L1 pathway and Treg-driven apoptosis in this model of tolerance (Figure 1).

For decades, efforts to reduce or eradicate inhibitor formation, i.e., to induce tolerance, have included treatment with repeated and high doses of FVIII (20). The protocol for immune tolerance induction (ITI) (21) to FVIII is costly, time consuming, and challenging for patients and their families. Moreover, ITI only succeeds clinically in approximately 70% of patients. Becker-Gotot, Meissner, et al. further explored the relevance of the ITI model to HemA therapy in two ways. First, they attempted a model of ITI in mice with repeated injections of FVIII in immunized HemA mice, leading to some diminution of inhibitor titers. This ITI-like protocol caused an expansion of PD-L1–expressing FVIII-specific-tetramer–positive induced Tregs in HemA mice, thus further implying a role of Tregs in self-tolerance to FVIII. Secondly, in a tour de force effort, they examined FVIII-binding B cells in both healthy adults and in one HemA patient who possessed inhibitors. It was necessary to use adults to obtain sufficient blood for analysis due to the rare frequency of such cells and difficulty in obtaining sufficient blood from young patients. Similar to results in mice, healthy donors had high levels of PD-1 mRNA in their FVIII-specific B cells, while PD-1 mRNA was not detectable in the FVIII-specific B cells of the HemA patient prior to ITI initiation. A few days after ITI was started, both PD-1 and Fas were undetectable in the patient’s FVIII-specific B cells. These results are anecdotal ($n = 1$), but suggestive of the results obtained in HemA mice. Further studies in a small cohort of patients suggested that ITI may establish PD-1–mediated immune tolerance and FVIII-specific Tregs in HemA patients.

Given that we can extrapolate from these data, the combination of both the murine studies in HemA and WT mice and preliminary results with HemA patients support the notion of a critical role for PD-1-mediated suppression as an important mechanism for tolerance.

**ITI for inhibitors**

ITI is an expensive and time-consuming process and, as noted, not universally successful. Moreover, the advent and increased usage of the bispecific antibody emicizumab (22), which bypasses FVIII to create a tenase complex, has led to a hot debate among hemophilia treaters about whether ITI should be attempted. But one should be aware that the maintenance of tolerance still requires the antigen (23), FVIII, since new B cells are continually

---

**Figure 1. A model for PD-1/PD-L1 pathway–driven immune tolerance.** The interaction of PD-L1 on Treg cells with PD-1 on antigen-specific B cells mediates tolerance via apoptosis, resulting in decreased numbers of B cells that are specific for self-antigens in healthy individuals. B cells from individuals with hemophilia A (HemA) can be stimulated to produce antibodies against FVIII. Repetitive injections of FVIII induces immune tolerance via a PD-1/PD-L1–mediated process in patients with HemA who have inhibitors.
being generated from bone marrow precursors. Hence, a hybrid model using emicizumab and low-dose FVIII treatment needs to be considered for patients who choose treatments with emicizumab (or other potential non-FVIII treatments to achieve hemostasis). Still, the results of Becker-Gotot, Meissner, et al. remind us that tolerance is an active process and that understanding and application of PD-1 and PD-1L-specific reagents may be useful to induce tolerance clinically, not only in the presence of hemophilia inhibitors but also in autoimmune diseases or other adverse immune responses.

**Acknowledgments**

The author’s work was supported in part by NIH grant R01 HL126727. I thank Kathleen Pratt and Martha Zuniga for critical comments on this Commentary and Ibo Janssens for contribution to the illustration. The opinions expressed are solely those of the author.

Address correspondence to: David W. Scott, Department of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, Maryland 20814, USA. Phone: 301.295.3618; Email: david.scott@usuhs.edu.

1. Hoyer LW. Hemophilia A. *N Engl J Med.* 1994;330(1):18-47.
2. Graw J, et al. Haemophilia A: from mutation analysis to new therapies. *Nat Rev Genet.* 2005;6(6):488-501.
3. Mannucci PM, Tuddenham EG. The hemophili-a—from royal genes to gene therapy. *N Engl J Med.* 2001;344(23):1773-1779.
4. Ehrenforth S, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. *Lancet.* 1992;339(8793):594-598.
5. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. *Adv Exp Med Biol.* 1995;386:35-45.
6. Pratt KF. Inhibitory antibodies in hemophilia A. *Curr Opin Hematol.* 2012;19(5):399-405.
7. Becker-Gotot J, et al. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. *J Clin Invest.* 2022;132(22):e159925.
8. Bi L, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. *Nat Genet.* 1995;10(1):119-121.
9. Qian J, et al. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. *Thromb Haemost.* 1999;81(2):240-244.
10. Miao CH. Immunomodulation for inhibitors in hemophilia A. *Expert Rev Hematol.* 2010;3(4):469-483.
11. Francisco LM, et al. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev.* 2010;236:219-242.
12. Gotot J, et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. *Proc Natl Acad Sci U S A.* 2012;109(26):10468-10473.
13. Goodnow CC, et al. Cellular and genetic mechanisms of self tolerance and autoimmunity. *Nature.* 2005;435(7042):590-597.
14. Nemazee D. Mechanisms and meaning of B-lymphocyte tolerance. *Res Immunol.* 1992;143(3):272-275.
15. Meeks SL, et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. *Blood.* 2012;120(12):2512-2520.
16. Skupsky J, et al. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. *Mol Ther.* 2010;18(8):1527-1535.
17. Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J.* 1992;11(11):3887-3895.
18. Agata Y, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. *Int Immunol.* 1996;8(5):765-772.
19. Jiang X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Mol Cancer.* 2019;18(1):10.
20. Mitchison NA. The dosage requirements for immunological paralysis by soluble proteins. *Immunology.* 1968;15(4):509-572.
21. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. *Lancet.* 1977;2(8044):933.
22. Kitazawa T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. *Nat Med.* 2012;18(10):1570-1574.
23. Chiller JM, et al. Pillars article: Kinetic differences in unresponsiveness of thymus and bone marrow cells. *Science.* 1971. 171: 813-815. *J Immunol.* 2013;191(8):989-991.